Thrombosis Research

• 

  Publication Venue For

  • Recognizing the risk of postpartum thrombosis among obese women and planning accordingly..  145:157-158. 2016
  • Effectiveness of homocysteine lowering vitamins in prevention of thrombotic tendency at high altitude area: A randomized field trial..  136:758-762. 2015
  • Characterization of antithrombin levels in pregnancy..  134:648-651. 2014
  • A mouse bleeding model to study oral anticoagulants..  133 Suppl 1:S6-S8. 2014
  • Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency..  133:629-633. 2014
  • Differences in thrombotic risk factors in black and white women with adverse pregnancy outcome..  133:108-111. 2014
  • Guidelines for treatment and prevention of venous thromboembolism among patients with cancer.  133:S122-S127. 2014
  • In vitro effects of recombinant activated factor VII on thrombin generation and coagulation following inhibition of platelet procoagulant activity by prasugrel..  132:106-111. 2013
  • Thrombosis in acute promyelocytic leukemia..  131:281-289. 2013
  • The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2..  129:793-796. 2012
  • Time dependence of clopidogrel loading effect: platelet activation versus platelet aggregation..  129:1-2. 2012
  • Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin..  127:576-581. 2011
  • Diagnosis and management of inherited von Willebrand disease in the next decade: panel discussion..  124 Suppl 1:S20-S21. 2009
  • Biological and pharmacological aspects of perioperative hemorrhagic complications associated with oral platelet-directed antithrombotic agents. Focus on isolated coronary artery bypass grafting and oral irreversible P2Y(12) receptor antagonists..  123:419-428. 2009
  • Association between thrombosis and bloodstream infection in neonates with peripherally inserted catheters..  122:782-785. 2008
  • Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation..  122:117-123. 2008
  • Platelet activation and its patient-specific consequences..  122:435-441. 2008
  • Some things I thought I knew about tissue factor that turn out to be wrong..  122 Suppl 1:S73-S77. 2008
  • Thrombophilia screening in asymptomatic children..  121:597-604. 2008
  • Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients..  121:107-115. 2007
  • Atherothrombosis at a distance: contributing role of existing large-burden vascular disease, circulating biosignals and modulating extravascular tissues..  119:761-768. 2007
  • Clopidogrel resistance?.  120:311-321. 2007
  • Delayed thrombin-induced platelet-fibrin clot generation by clopidogrel: a new dose-related effect demonstrated by thrombelastography in patients undergoing coronary artery stenting..  119:563-570. 2007
  • High altitude: a hypercoagulable state: results of a prospective cohort study..  120:391-397. 2007
  • Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia..  120:117-126. 2007
  • Hemostatic activation in a chemically induced rat model of severe hemolysis and thrombosis..  118:747-753. 2006
  • Thrombosis Research: Preface.  117:1-3. 2005
  • Clinical implications for patients on antithrombotic therapy while taking supplements..  117:75-80. 2005
  • Dialogue with patient care organizations..  117:211-222. 2005
  • The difference between clopidogrel responsiveness and posttreatment platelet reactivity..  115:89-94. 2005
  • Clopidogrel does not induce fibrinolysis in healthy subjects..  114:97-100. 2004
  • Evaluation of a novel kallikrein inhibitor on hemostatic activation in vitro..  113:333-339. 2004
  • The stratification of platelet reactivity and activation in patients with stable coronary artery disease on aspirin therapy..  112:9-12. 2003
  • Heparin prevents xylum clot signature analyser to detect platelet inhibition with clopidogrel during coronary stenting [2].  102:95-97. 2001
  • Clinical utility of the platelet function analyzer (PFA-100) for the assessment of the platelet status in patients with congestive heart failure (EPCOT trial)..  101:427-433. 2001
  • Platelet function and total length of intracoronary stents: is there a correlation?.  101:105-107. 2001
  • Initial platelet activity may predict efficacy after chronic oral glycoprotein IIb/IIIa blockade: should we still consider uniform treatment regimens?.  99:105-107. 2000
  • The flow cytometer model markedly affects measurement of ex vivo whole blood platelet-bound P-selectin expression in patients with chest pain: are we comparing apples with oranges..  96:51-56. 1999
  • Storing paraformaldehyde-fixed whole blood patient samples after chronic platelet glycoprotein IIb/IIIa blockade: core laboratory considerations..  95:201-203. 1999
  • Moderate hyperhomocyst(e)inemia is associated with the presence of coronary artery disease and the severity of coronary atherosclerosis in Koreans..  94:45-52. 1999
  • Assessment of platelet activity by measuring platelet-derived substances in plasma from patients with acute myocardial infarction: surprising lessons from the GUSTO-III Platelet Study..  93:149-150. 1999
  • S-nitrosoglutathione/glutathione disulphide/Cu2+-dependent stimulation of L-arginine transport in human platelets..  91:113-120. 1998
  • Myths and realities of P-selectin plasma levels in patients with acute myocardial infarction..  88:343-344. 1997
  • Variability in platelet procoagulant activity in healthy volunteers..  81:533-543. 1996
  • An animal model of fibrinolytic bleeding based on the rebleed phenomenon: application to a study of vulnerability of hemostatic plugs of different age..  67:31-40. 1992
  • Effects of 9, 12, 15-octadecatrien-6-ynoic acid on the metabolism of arachidonic acid in platelets and on platelet aggregation..  65:687-698. 1992
  • Recombinant hirudin displaces human factor Xa from its endothelial binding sites..  57:803-806. 1990
  • Lipoprotein(a) inhibition of plasminogen activation by tissue-type plasminogen activator..  57:155-162. 1990
  • Production of chemotactic peptides by neutrophil degradation of heparin cofactor II..  57:77-85. 1990
  • Human mononuclear phagocyte transglutaminase activity cross-links fibrin..  55:57-68. 1989
  • The effect of phosphatidylserine on the inhibition of human factor Xa by the plasma proteinase inhibitors..  50:901-906. 1988
  • The macrophage-mediated regulation of hepatocyte synthesis of antithrombin III and alpha 1-proteinase inhibitor..  41:707-715. 1986
  • Precipitation of fibrinogen, fibrinogen degradation products and fibrin monomer by histone H3..  39:97-116. 1985
  • In vitro effects of acetaminophen and its analogues on human platelet aggregation and thromboxane B2 synthesis..  38:33-43. 1985
  • Inhibitory effect of ristocetin and factor VIII/von Willebrand factor protein on human platelet adenylate cyclase activity..  30:301-308. 1983
  • Lack of thromboxane A2 synthesis in platelet aggregation induced by factor VIII/von Willebrand factor..  24:245-251. 1981
  • The bleeding diathesis in human glycogen storage disease type I: in vitro identification of a naturally occurring inhibitor of ristocetin-induced platelet aggregation..  18:683-692. 1980
  • Effectiveness of intermittent pulsatile elastic stockings for the prevention of calf and thigh vein thrombosis in patients undergoing elective knee surgery..  16:37-45. 1979
  • Streptokinase-induced degradation of crosslinked and uncrosslinked clots..  13:569-575. 1978
  • Catabolism of antithrombin III-protease complexes..  32:253-254. 1983
  • Guidelines for bleeding disorders in women. 2009
  • 4B.3 Management of valvular heart disease in pregnancy 2007
  • More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease. 2007